Navigation Links
Lab Tests Throw Up New Path for Parkinson's

Finnish doctors say they have identified a new protein that, in rats, rescues brain cells whose death causes Parkinson's disease , the tragic degenerative disorder of the central nervous system.

The new molecule, called conserved dopamine neurotrophic factor (CDNF), prevents the degeneration of cells that produce the key brain chemical dopamine and can even help damaged cells to recover.

Tested on lab rodents engineered to have Parkinson's, CDNF "was at least as efficient" as GDNF (glial cell-derived neurotrophic factor), which until now has generated the most excitement in this field, they say.

The findings are published on Thursday in a letter to Nature, the British science journal, by a team led by Mart Saarma of the University of Finland.

Parkinson's causes uncontrollable shaking, along with impaired speech and movement. In approximately one third of cases it also results in dementia. The disease affects at least one percent of people over the age of 65.

Dopamine, which helps direct movement, is provided in a part of the brain called the substantia nigra.

Attempts to treat Parkinson's have focussed mainly on a pharmaceutical substitute for dopamine or on restoring or protecting dopamine-producing cells.


'"/>




Page: 1

Related medicine news :

1. The Effectiveness Of Screening Tests Questioned
2. Blood Tests Can Help Detect Osteoporosis Early In Life
3. Easier Tests To Detect Tuberculosis
4. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
5. Genetic Tests Could Become As Affordable As Blood Tests
6. Obese Adults Undergo Less Medical Tests And More Vulnerable To Diseases
7. Delay in Breast Cancer Gene Tests
8. Health Officials Inquire Into OraQuick HIV Tests
9. Move to make HIV Tests mandatory For Soldiers In Northeast
10. Punjab Government To Clamp Down On Sex Determination Tests
11. Free HIV Tests Brings Crowd to the Testing Centers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Lab Tests Throw New Path for Parkinson

(Date:7/25/2008)...e/ -- Klafter & Olsen LLP has filed a,class action...re" or the,"Company") (Nasdaq: ARTC ) and certain...e Western District of Texas on behalf of all perso...roCare from January 24, 2008,through July 18, 2008...ll,persons or entities who purchased call options ...
(Date:7/25/2008)...iretroviral therapy may be due to genetic factors ...A new study challenges the long-held belief that t...em,s ability to restore itself after HIV patients ...apy (HAART). , From 50 percent to 90 percent of...V. Intravenous drug use is the main cause of both ...
(Date:7/25/2008)...- BeaconEquity.com announces the,availability of T...rs can view all of the daily trading notes for fre...,s Trade Alerts include: DUSA Pharmaceuticals Inc..... (Nasdaq: MBRK ), NovaMed Inc. (Nasdaq:,NOVA), A...daq: AFFX ) and,Abaxis Inc. (Nasdaq: ABAX )., J...
(Date:7/25/2008)...gnificant Improvements in Members, Health, ATLANT...er in health,care quality management solutions for...s entered into a long-term agreement with Wellmark...tion on Quality(SM) Incent and,Reward Best Practic...d,primary care clinicians to promote improved qual...
Breaking Medicine News(10 mins):Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3
... fish at least once a month can minimise the risk ...d researchers. Around 607 participants developed...dy involving more than 43,005 men aged 39 to 76. I...clot that blocks the blood vessel supplying the br...
...ug fluvoxamine has been found by researchers to be...od shifts in women with borderline personality dis...renic, non-bipolar women with borderline// persona...onducted by researchers from various universities ...
...evious research evidence that HRT could reduce ris...n reversed by a recent study of 1000 women of ages...r in the United Kingdom.The aim of the study was t...and progesterone reduced the risk of future heart ...
...chers in there study are trying to observe why su...e but studies are ongoing. It's long been known th...and other mental functions after an operation// - ...function (POCD).Often relatives will say that the ...
Other Medicine News:
(Date:7/22/2008)...July 22 /- Following a,thor...rd of Progen,Pharmaceuticals Limited (ASX: PGL; Na...ed the PI-88 phase 3 study in liver cancer. Progen...existing portfolio of compounds and,the company wi...nd,opportunities through Merger & Acquisition acti...
(Date:7/22/2008)...herapeutics Development Initiative bring MJFF,s,cu...eadline January 20,2009, NEW YORK, July 22 /PRNe...eed delivery of transformative treatments and a cu...ndation for Parkinson,s Research has awarded,$2.7 ...teams. The awards,were granted under MJFF,s Therap...
(Date:7/22/2008)...tudy Confirms Tyrima Exhibits Excellent Drug-Like ...Results Support Initiation of Phase II Clinical Tr...Newswire/ -- CeNeRx BioPharma,Inc., a clinical st...ive,treatments for diseases of the central nervous... candidate Tyrima(TM) into Phase II trials for the...
(Date:7/22/2008)...Calif., July 22 /- Hyperion,Therapeut...tient enrollment,in its Phase 1/2 clinical trial t...avenging effects of HPN-100 (formally called GT4P)...ients with urea cycle disorders,(UCD). The company...quarter,of this year., (Logo: http://www.newscom...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Many African Americans have a gene that prolongs life after heart failure 2966 1Many African Americans have a gene that prolongs life after heart failure 2966 2Many African Americans have a gene that prolongs life after heart failure 2966 3Many African Americans have a gene that prolongs life after heart failure 2966 4Allergies Can Dig Into Gardenings Fun 17255 1Allergies Can Dig Into Gardenings Fun 17255 2BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 1BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 2BIOTECON Diagnostics and MERCK KGaA start worldwide marketing alliance 4712 3Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 1Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 2Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 3Angiotechs Corporate Partner Boston Scientific Reports Canadian Approval for TAXUS 28R 29 Liberte 28R 29 Stent System 4710 4
...BRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - AVE...ny focused on the,discovery and development of nov...t it will present a total of 12 oral and poster,pr... Research,(AACR) Annual Meeting on April 14-18, 20...ted to share with the cancer community the,pioneer...
...NDON, April 12, 2007--The costs of eradicating,pol...while high in,the short term, are much lower than ...s without eradication. And a recently developed,mo...ive against,type 1 poliomyelitis than an existing ...rticles published Online and in an upcoming,issue ...
Other Medicine Technology:AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR 2AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR 3Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
Stainless Steel
2 Sided Pivoted Closed Ring Design,Pointed And Smooth Sides; in stainless steel.
The e.cam single-detector system offers general purpose scanning flexibility with unrestricted access for gurneys and wheelchairs. This cost-effective system features a clinically versatile open gant
In Stainless steel. Available in 1.5, 2.0,3.0 & 3.5 MM
Medicine Products: